Heart Attack Outcomes Are Similar With Anti-Clotting Drugs And Balloon Angioplasty, University Of Washington Study Shows

October 24, 1996

Heart attack patients admitted to community hospitals show nearly identical survival rates, whether treated with powerful anti-clotting drugs or with balloon angioplasty.

This conclusion is drawn by University of Washington researchers publishing results of their study of more than 3,000 patients in the Oct. 24 issue of the New England Journal of Medicine.

Using data gathered as part of the UW's Myocardial Infarction Triage and Intervention (MITI) Project, the researchers compared the death rates, both during hospitalization and over the following three years, among 2,095 patients treated with thrombolytic therapy and 1,050 patients treated with primary angioplasty , at 19 Seattle-area hospitals between 1988 and 1994.

They found no difference in mortality, either in the hospital or after release, between those treated with drug therapy and those treated with primary angioplasty (so-called when performed within the first few hours), said Dr. Nathan R. Every, UW assistant professor of medicine and lead author of the study. The death rate was 5.6 percent for patients treated with anti-clotting drugs versus 5.5 percent for patients treated with angioplasty.

Balloon angioplasty is a procedure increasingly used by cardiologists in the first hours after a heart attack. "There has been a substantial increase in the use of primary angioplasty since publication of several randomized trials in 1993 that showed patients treated with the procedure had lower hospital mortality than those treated with thrombolytic therapy," said Every. But he noted that these earlier studies were done at medical centers that perform more primary angioplasties than the average community hospital.

"Many community cardiologists used the results of these trials to switch from thrombolytic therapy to primary angioplasty," said Every. "We undertook the study in part because we were concerned that results in the community may not be quite as good as those in the published trials. We are also concerned that there may be a delay in treatment when community hospitals feel the need to transport patients to a center that performs large numbers of angioplasties."

The study also showed that medical costs, as well as the number of additional procedures, were lower among patients treated with thrombolytic therapy, in both the short and the long term. There were 33 percent fewer coronary angiograms, 20 percent fewer coronary angioplasties, and 14 percent lower medical costs after three years of follow-up. Hospital costs averaged $3,000 less among patients receiving drug therapy.

"From our results," said Every, "we feel that hospitals should decide which strategy is best for them, and develop expertise either in delivering the drug or in performing angioplasty quickly. Hospitals should not feel obligated to start a primary angioplasty program or transfer patients (to a large medical center) to undergo this procedure."

"Cardiologists have taken hold of primary angioplasty," said Every. "The argument is that it saves more lives. Our message is that the two therapies are equally effective."

Every's co-investigators were Lori S. Parsons, Dr. Mark Hlatky, Jenny Martin and Dr. W. Douglas Weaver, director of the MITI Project. The research was supported by the Department of Veterans Affairs, the National Heart, Lung and Blood Institute, and the Agency for Health Care Policy and Research.

University of Washington

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.